AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 21 min read$AXSM

Axsome Therapeutics GAAP EPS of -$0.25 beats by $0.38, revenue of $259.7M beats by $10.51M (AXSM:NASDAQ)

Axsome Therapeutics reported Q3 GAAP EPS of -$0.25, beating estimates by $0.38. Revenue was $259.7M, up 51.9% year-over-year and $10.51M above expectations. Shares rose 2.5% post-market.

Original reporting
seekingalpha.com
Published Nov 2, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AXSM
Bullish
high confidence
Mentioned
$AXSM
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The earnings beat reinforces confidence in Auvelity's market traction, likely supporting short‑term price gains.

02

Market read

Earnings beat provides a fresh catalyst for AXSM, prompting immediate post‑market price appreciation and potential continued upside.

03

What to watch

Potential upcoming competition for Auvelity and regulatory scrutiny could temper upside.

Relevance 7/10Novelty 8/10Timing: after‑hours

Background

Axsome Therapeutics reported its Q3 2026 earnings, highlighting a GAAP EPS beat and revenue growth, with shares up 2.5% post‑market.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Q3 GAAP EPS of -$0.25 beats expectations by $0.38 and revenue of $259.7M beats by $10.51M, driving a 2.5% post‑market share rise.

Expected impact

upward pressure as the market prices in the earnings beat and revenue growth

Evidence & confidence

Both EPS and revenue exceeded consensus, and the stock already rose 2.5% after hours, indicating positive trader sentiment.

Market effects

Sector

Positive signal for the biotech/psychiatric drug sector, may lift peers with similar pipelines.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Modest, confined to biotech and specialty pharma investors.

Counterpoint

What could challenge this read

If the beat is driven by one product, underlying pipeline risk remains; caution on sustainability.

Key entities

  • company
    Axsome Therapeutics

    Biopharma focused on central nervous system disorders.

Read at source← All news

StoryAxsome reports strong Q3 growth as AUVELITY sales accelerate

Also covered by

3 outlets

Related articles

NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMed

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics reported Q3 earnings, with R&D expenses rising to $50.6M and SG&A to $203.1M. AUVELITY prescriptions grew 40% YoY, while SYMBRAVO and SUNOSI also saw increases. The company expects cash to fund operations until cash-flow positivity. Axsome outlined 2027 milestones, including FDA review of AXS-12 and trials for AXS-05, solriamfetol, and AXS-20.

finance.yahoo.com2 min